7,500 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Argentarii LLC

Argentarii LLC acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 7,500 shares of the specialty pharmaceutical company’s stock, valued at approximately $271,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SUPN. Smartleaf Asset Management LLC increased its position in Supernus Pharmaceuticals by 219.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 870 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth $72,000. Venturi Wealth Management LLC purchased a new position in Supernus Pharmaceuticals during the fourth quarter worth $92,000. KBC Group NV increased its position in Supernus Pharmaceuticals by 53.1% during the fourth quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company’s stock worth $97,000 after buying an additional 929 shares in the last quarter. Finally, Kennebec Savings Bank purchased a new position in Supernus Pharmaceuticals during the third quarter worth $103,000.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 700 shares of Supernus Pharmaceuticals stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at $402,103.38. The trade was a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This represents a 10.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock valued at $440,263 over the last quarter. Company insiders own 9.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on SUPN shares. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday.

Supernus Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ:SUPN opened at $32.07 on Monday. The company has a market cap of $1.79 billion, a P/E ratio of 29.97 and a beta of 0.83. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The business has a fifty day simple moving average of $36.70 and a 200-day simple moving average of $35.28.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.